Article
Gene-agnostic approaches to treating inherited retinal degenerations
13 Apr 2023
Abstract excerpt
Most patients with inherited retinal degenerations (IRDs) have been waiting for treatments that are "just around the corner" for decades, with only a handful of seminal breakthroughs happening in recent years. Highlighting the difficulties in the quest for curative therapeutics, Luxturna required 16 years of development before finally obtaining United States Food and Drug Administration (FDA) approval and its...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
